Avalo Therapeutics Q2 EPS $(0.83) Misses $(0.58) Estimate
Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.58) by 43.1 percent. This is a 56.77 percent increase over losses of $(1.92) per share
Avalo lost more money per share than experts expected, which is disappointing news. But the company is actually losing *less* money than it did a year ago, which shows it's moving in a better direction.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.